Marco A, Domínguez-Hernández R, Casado MA
Clinical and economic impact of the treatment of chronic hepatitis C in prison inmates in Spain
21st Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Barcelona. 10-14 nov 2018
García F, Domínguez-Hernández R, Alados JC, Casado M, Macías J, Téllez F, Pascasio JM, Casado MA
Healthcare outcomes of one-step diagnosis in patients with chronic hepatitis C
21st Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Barcelona. 10-14 nov 2018
Capel M, Ciudin A, Mareque M, Rodríguez-Rincón RM, Oyagüez I
Cost-effectiveness analysis of exenatide versus GLP-1 receptor agonists in patients with type 2 Diabetes Mellitus
21st Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Barcelona. 10-14 nov 2018
de Andrés-Nogales F, Oyagüez I, Suárez C, López-Sendón JL, González-Juanatey JR, Suarez J, Polanco C
Cost-effectiveness analysis of apixaban versus edoxaban for stroke prevention in non-valvular atrial fibrillation Spanish patients
21st Annual European Congress International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Barcelona. 10-14 nov 2018
Marco A, Domínguez-Hernández R, Casado MA
Cost-Effectiveness Analysis of the Treatment for Chronic Hepatitis C in Spanish Prisoners
69th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). San Francisco, EEUU. 9-13 nov 2018
García F, Domínguez-Hernández R, Alados JC, Casado M, Macías J, Téllez F, Pascasio JM, Casado MA
La simplificación del proceso de diagnóstico de la hepatitis C crónica es una estrategia coste-efectiva
IV Congreso nacional del grupo de estudio de hepatitis víricas (GEHEP) de la SEIMC. Córdoba. 27-29 sep 2018
Capel M, Mareque M, Álvarez CJ, Oyagüez I
Cost-effectiveness of fixed-dose combinations therapies for chronic obstructive pulmonary disease treatment
Clin Drug Investig (2018) 38:611-620
Capel M, Ciudin A, Mareque M, Rodríguez-Rincón RM, Oyagüez I
Coste-efectividad de exenatida frente a agonistas del receptor GLP-1 en pacientes con diabetes mellitus tipo 2
XXIX Congreso Nacional de la Sociedad Española de Diabetes. Oviedo. 18-20 abr 2018
Buti M, Domínguez-Hernández R, Casado MA, Sabater E, Esteban R